The Medicines Company (MDCO) Shares Bought by Bailard Inc.

Bailard Inc. lifted its stake in shares of The Medicines Company (NASDAQ:MDCO) by 115.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,000 shares of the company’s stock after purchasing an additional 37,500 shares during the quarter. Bailard Inc.’s holdings in The Medicines were worth $2,094,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. OppenheimerFunds Inc. raised its holdings in shares of The Medicines by 0.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 707,160 shares of the company’s stock worth $25,953,000 after acquiring an additional 1,777 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in shares of The Medicines by 2.6% in the 2nd quarter. State of Wisconsin Investment Board now owns 70,100 shares of the company’s stock worth $2,573,000 after acquiring an additional 1,800 shares during the last quarter. Aperio Group LLC raised its holdings in shares of The Medicines by 8.5% in the 2nd quarter. Aperio Group LLC now owns 28,013 shares of the company’s stock worth $1,028,000 after acquiring an additional 2,203 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of The Medicines by 24.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,095 shares of the company’s stock worth $481,000 after acquiring an additional 2,550 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of The Medicines by 7.4% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 43,419 shares of the company’s stock worth $1,593,000 after acquiring an additional 2,990 shares during the last quarter.

NASDAQ:MDCO opened at $22.05 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -2.63 and a beta of 1.02. The Medicines Company has a 52 week low of $19.55 and a 52 week high of $41.57.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.13). The firm had revenue of ($3.30) million during the quarter, compared to analysts’ expectations of $1.88 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The company’s quarterly revenue was down 141.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.19) EPS. Equities analysts forecast that The Medicines Company will post -2.91 earnings per share for the current year.

A number of research firms recently weighed in on MDCO. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the stock a “buy” rating in a report on Thursday, August 16th. BidaskClub lowered shares of The Medicines from a “buy” rating to a “hold” rating in a report on Tuesday, August 28th. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 30th. Citigroup upped their target price on shares of The Medicines from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, August 20th. Finally, ValuEngine lowered shares of The Medicines from a “buy” rating to a “hold” rating in a report on Monday, September 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $52.75.

In other news, EVP Christopher T. Cox acquired 50,300 shares of the firm’s stock in a transaction on Friday, November 16th. The stock was purchased at an average price of $19.73 per share, for a total transaction of $992,419.00. Following the purchase, the executive vice president now owns 60,308 shares in the company, valued at approximately $1,189,876.84. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 10.29% of the company’s stock.

WARNING: This report was posted by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.wkrb13.com/2018/12/07/the-medicines-company-mdco-shares-bought-by-bailard-inc.html.

About The Medicines

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply